Literature DB >> 19884959

The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.

Stacy Loeb1, Anna Kettermann, Luigi Ferrucci, Patricia Landis, E Jeffrey Metter, Ballentine H Carter.   

Abstract

Entities:  

Year:  2008        PMID： 19884959      PMCID： PMC2603630          DOI： 10.1016/j.eururo.2008.07.069

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  8 in total

1.  Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity.

Authors:  Axel Heidenreich
Journal:  Eur Urol       Date:  2008-07-02       Impact factor: 20.096

2.  Does PSA velocity predict prostate cancer in pre-screened populations?

Authors:  Fritz H Schröder; Monique J Roobol; Theo H van der Kwast; Ries Kranse; Chris H Bangma
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

3.  Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.

Authors:  H Ballentine Carter; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

4.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

5.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

6.  Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Authors:  David Ulmert; Angel M Serio; Matthew F O'Brien; Charlotte Becker; James A Eastham; Peter T Scardino; Thomas Björk; Göran Berglund; Andrew J Vickers; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

7.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

8.  Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.

Authors:  H B Carter; J D Pearson; Z Waclawiw; E J Metter; D W Chan; H A Guess; P C Walsh
Journal:  Urology       Date:  1995-04       Impact factor: 2.649
  8 in total
  1 in total

1.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.